Alcina Navarro Alejandro, Gómez Valero Sara, Gimeno Del Sol Mercedes, Coronel Granado María Pilar
Rehabilitation Department, Hospital Universitario del Henares, Coslada, Madrid, Spain.
Scientific Department, Meiji Pharma Spain, Alcalá de Henares, Madrid, Spain.
Open Access Rheumatol. 2024 Mar 21;16:67-73. doi: 10.2147/OARRR.S446572. eCollection 2024.
The entry into force of the new Medical Device Regulation (EU) 2017/745 highlights the need for post-market clinical follow-up to ensure the safety and efficacy throughout the life cycle of medical devices. This study evaluates the efficacy and safety of a single intra-articular hyaluronic acid injection in knee osteoarthritis in real-world conditions, over a six-month period, aligning with the summary of safety and clinical performance (SSCP) required by the new regulation.
Patients over 18 years of age with knee osteoarthritis, treated with a single injection of HA (Adant One, Meiji Pharma Spain, Spain) at a 3rd level hospital. Patients were treated and followed between January 1, 2020 and June 30, 2022. Demographic, clinical, and treatment-related data were collected, and efficacy regarding pain relief and/or function improvement was assessed using a Likert-type scale. Data were pseudo-anonymized and the comparison was performed using Fisher' or Mann Whitney' test. The study was approved by the Ethics Review Board of the Hospital Puerta de Hierro (Madrid, Spain).
We followed 20 patients with knee osteoarthritis, with a mean age of 61 years, 80% women, and with a high burden of comorbidities (90%). A total of 60% of patients presented Kellgren-Lawrence grade III-IV. Four patients (20%) returned before 6 months due to lack of efficacy. Of the other patients, 65% showed a clinical response that lasted more than 12 months in 38.5% of cases. Time until medical appointment and taking concomitant medication for knee osteoarthritis were associated with better clinical response (p < 0.05).
The administration of a Adant One single intra-articular hyaluronic acid injection in knee osteoarthritis is effective, safe, and maintains the improvement over a six-month period. Our findings also emphasize the need of using standardized tools for accurate efficacy assessment and optimal patient care.
新的《医疗器械法规》(欧盟)2017/745的生效凸显了上市后临床随访的必要性,以确保医疗器械在整个生命周期内的安全性和有效性。本研究评估了在现实世界条件下,单次关节腔内注射透明质酸治疗膝关节骨关节炎六个月的疗效和安全性,符合新法规要求的安全和临床表现摘要(SSCP)。
在一家三级医院,对18岁以上的膝关节骨关节炎患者进行单次注射透明质酸(Adant One,明治制药西班牙公司,西班牙)治疗。患者于2020年1月1日至2022年6月30日期间接受治疗和随访。收集人口统计学、临床和治疗相关数据,并使用李克特量表评估疼痛缓解和/或功能改善方面的疗效。数据进行了伪匿名处理,并使用Fisher检验或Mann-Whitney检验进行比较。该研究获得了西班牙马德里铁之门医院伦理审查委员会的批准。
我们对20例膝关节骨关节炎患者进行了随访,平均年龄61岁,80%为女性,合并症负担较高(90%)。共有60%的患者为Kellgren-Lawrence III-IV级。4例患者(20%)因疗效不佳在6个月前复诊。在其他患者中,65%在38.5%的病例中表现出持续超过12个月的临床反应。直到预约就医的时间和服用膝关节骨关节炎的伴随药物与更好的临床反应相关(p<0.05)。
在膝关节骨关节炎中单次关节腔内注射Adant One透明质酸有效、安全,并在六个月内维持改善效果。我们的研究结果还强调了使用标准化工具进行准确疗效评估和优化患者护理的必要性。